Female hair loss

Female hair loss is a diffuse thinning pattern in women. The approach carries hormonal nuances that differ from male-pattern loss, so the doctor reviews your full case before suggesting any treatment.

​

Treatments a doctor considers

A licensed doctor decides case by case. We never prescribe without evaluation.

​

Your path to treatment

​

How Hi-Doctor handles it

You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications. See how the consultation works, how we handle safety and eligibility, and pricing for hair-growth consultations.

​

Pathophysiology and diagnostic approach

Female pattern hair loss (FPHL) shares the final pathway of follicular miniaturisation with male androgenetic alopecia but differs in its hormonal milieu, inheritance pattern, and clinical presentation (PMID 30627618). In FPHL, thinning is diffuse over the crown and frontal scalp, with preservation of the frontal hairline — described as a “Christmas tree” pattern on the Olsen classification. The Ludwig and Sinclair scales are used to grade severity. The role of androgens in FPHL is less clear-cut than in male AGA: many women with FPHL have normal circulating androgen levels, suggesting that the condition may result from increased intrafollicular androgen metabolism or from a lower threshold of androgen sensitivity in the dermal papilla, rather than systemic hyperandrogenaemia. A diagnosis of FPHL can usually be confirmed by history (gradual onset, pattern of diffuse central thinning) and clinical examination (frontocentral accentuation, frontal hairline intact). Scalp biopsy is rarely needed but, when performed, shows an increased telogen:anagen ratio, follicular miniaturisation, and perifollicular lymphocytic infiltration. In women who also present with signs of hyperandrogenism — hirsutism, acne, menstrual irregularity — the doctor may recommend investigation for polycystic ovary syndrome (PCOS), non-classical congenital adrenal hyperplasia, or an androgen-secreting tumour; measurement of total and free testosterone, sex hormone-binding globulin (SHBG), 17-hydroxyprogesterone, and dehydroepiandrosterone sulphate (DHEAS) can help distinguish these. Thyroid function, ferritin, vitamin D, and zinc levels are optional but commonly assessed, as iron deficiency and thyroid dysfunction can mimic or exacerbate FPHL. The distinction from telogen effluvium is important: FPHL is chronic and progressive, whereas telogen effluvium is acute and self-limiting, with diffuse shedding occurring 2–3 months after a trigger such as illness, childbirth, or stress.

​

Treatment considerations

Topical minoxidil is the only medicine specifically licensed for FPHL in women in the EU. Oral minoxidil at low doses is used off-label and requires monitoring for hypertrichosis, pedal oedema, and palpitations. Antiandrogen options include spironolactone and finasteride, though the evidence for finasteride in FPHL is less robust than in men: randomised trials have shown benefit predominantly in postmenopausal women, possibly because premenopausal women with normal androgen levels have a different intrafollicular androgen milieu that is less responsive to 5α-reductase inhibition (PMID 30627618). Spironolactone, a mineralocorticoid receptor antagonist with antiandrogen properties at higher doses, is the most commonly prescribed antiandrogen for FPHL in women; it reduces follicular testosterone binding and is titrated with monitoring of serum potassium and blood pressure. The reviewing doctor considers the woman’s age, menopausal status, contraceptive use (spironolactone and finasteride are contraindicated in pregnancy), and concurrent hyperandrogenism when selecting a treatment.

​

Start a consultation